For the quarter ending 2026-03-31, TYRA has $412,040K in assets. $24,465K in debts. $84,955K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 84,955 | 77,387 | 61,951 | 98,490 |
| Marketable securities | 298,511 | 178,616 | 212,973 | 197,781 |
| Prepaid expenses and other current assets | 11,147 | 9,447 | 6,292 | 5,884 |
| Total current assets | 394,613 | 265,450 | 281,216 | 302,155 |
| Restricted cash | 884 | 1,000 | 1,000 | 1,000 |
| Property and equipment, net | 1,215 | 1,314 | 1,346 | 1,413 |
| Right-of-use asset | 5,443 | 5,573 | 5,699 | 5,822 |
| Other long-term assets | 9,885 | 9,272 | 12,590 | 11,109 |
| Total assets | 412,040 | 282,609 | 301,851 | 321,499 |
| Accounts payable | 3,642 | 1,178 | 1,991 | 2,245 |
| Lease liabilities, current | 488 | 472 | 456 | 441 |
| Accrued expenses and other current liabilities | 15,126 | 16,444 | 13,432 | 11,084 |
| Total current liabilities | 19,256 | 18,094 | 15,879 | 13,770 |
| Other long-term liabilities | - | 0 | 0 | 0 |
| Lease liabilities, noncurrent | 5,209 | 5,338 | 5,463 | 5,582 |
| Total liabilities | 24,465 | 23,432 | 21,342 | 19,352 |
| Common stock, 0.0001 par value 500,000,000 shares authorized at march 31, 2026 and december 31, 2025 53,706,357 and 50,754,262 shares issued at march 31, 2026 and december 31, 2025, respectively, and 53,706,357 and 50,749,945 shares outstanding at march 31, 2026 and december 31, 2025, respectively | 6 | 5 | 5 | 5 |
| Additional paid-in capital | 798,025 | 630,037 | 617,486 | 609,262 |
| Accumulated other comprehensive income | 107 | 393 | 442 | 436 |
| Accumulated deficit | -410,563 | -371,258 | -337,424 | -307,556 |
| Total stockholders' equity | 387,575 | 259,177 | 280,509 | 302,147 |
| Total liabilities and stockholders' equity | 412,040 | 282,609 | 301,851 | 321,499 |
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)